Early Phase 2 Clinical Results of IL-15RαFc Superagonist N-803 With Bacillus Calmette-Guérin (BCG) in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC) Patients Demonstrating 86% CR of Carcinoma In Situ (CIS)